Sentinel lymph node biopsy and melanoma: 2010 update. Part II

Journal of the American Academy of Dermatology

Volumn 62, Issue 5, 2010, Pages 737-748

  Stebbins, William G ^a   Garibyan, Lilit ^a   Sober, Arthur J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

melanoma; Multicenter Selective Lymphadenectomy Trial; sentinel lymph node biopsy

Indexed keywords

CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE DISSECTION; LYMPHADENECTOMY; MELANOMA; METASTASIS; MORBIDITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE BIOPSY;

ALGORITHMS; CLINICAL TRIALS AS TOPIC; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; MELANOMA; NEOPLASM STAGING; PATIENT SELECTION; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 77950574132     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.11.696     Document Type: Review

References (69)

1. Kretschmer L., Hilgers R., Möhrle M., Balda B.R., Breuninger H., Konz B., et al. Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphonodectomy and early excision of their nodal disease. Eur J Cancer 40 (2004) 212-218
2. Starz H., Siedlecki K., and Balda B.R. Sentinel lymphonodectomy and s-classification: a successful strategy for better prediction and improvement of outcome of melanoma. Ann Surg Oncol 11 3 suppl (2004) 162S-168S
3. Morton D.L., Hoon D.S., Cochran A.J., Turner R.R., Essner R., Takeuchi H., et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 238 (2003) 538-549
4. Cascinelli N., Morabito A., Santinami M., MacKie R.M., and Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 351 (1998) 793-796
5. Kretschmer L., Beckmann I., Thoms K.M., Haenssle H., Bertsch H.P., and Neumann C. Sentinel lymphonodectomy does not increase the risk of loco-regional cutaneous metastases of malignant melanomas. Eur J Cancer 41 (2005) 531-538
6. Johnson T.M., Sondak V.K., Bichakjian C.K., and Sabel M.S. The role of sentinel lymph node biopsy for melanoma: evidence assessment. J Am Acad Dermatol 54 (2006) 19-27
7. Gutzmer R., Al Ghazal M., Geerlings H., and Kapp A. Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients. Br J Dermatol 153 (2005) 1137-1141
8. Rutkowski P., Nowecki Z.I., Nasierowska-Guttmejer A., and Ruka W. Lymph node status and survival in cutaneous malignant melanoma-sentinel lymph node biopsy impact. Eur J Surg Oncol 29 (2003) 611-618
9. Nowecki Z.I., Rutkowski P., and Michej W. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3). Ann Surg Oncol 15 (2008) 2223-2234
10. van Akkooi A.C., Bouwhuis M.G., de Wilt J.H., Kliffen M., Schmitz P.I., and Eggermont A.M. Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma. Br J Surg 94 (2007) 1293-1299
11. Morton D.L., Thompson J.F., Cochran A.J., Mozzillo N., Elashoff R., Essner R., et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 355 (2006) 1307-1317
12. Balch C.M., Soong S., Ross M.I., Urist M.M., Karakousis C.P., Temple W.J., et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 7 (2000) 87-97
13. Morton D.L., Cochran A.J., Thompson J.F., and Sondak V.K. Sentinel lymph node and regional micrometastases. In: Balch C.M., Houghton A.N., Sober A.J., Soong S., Atkins M.B., and Thompson J.F. (Eds). Cutaneous Melanoma (2009), Quality Medical Publishing, St Louis 373-386
14. Ross M.I., and Gershenwald J.E. How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)?. Ann Surg Oncol 15 (2008) 670-673
15. Kretschmer L., and Hilgers R. Research supports the view that sentinel node biopsy is the standard of care in high-risk primary melanoma. J Clin Oncol 24 (2006) 2965-2966
16. Estourgie S.H., Nieweg O.E., and Kroon B.B. High incidence of in-transit metastases after sentinel node biopsy in patients with melanoma. Br J Surg 91 (2004) 1370-1371
17. Pawlik T.M., Ross M.I., Thompson J.F., Eggermont A.M., and Gershenwald J.E. The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol 23 (2005) 4588-4590
18. Thomas J.M., and Clark M.A. Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma. Eur J Surg Oncol 30 (2004) 686-691
19. van Poll D., Thompson J.F., Colman M.H., McKinnon J.G., Saw R.P., Stretch J.R., et al. A sentinel node biopsy does not increase the incidence of in-transit metastasis in patients with primary cutaneous melanoma. Ann Surg Oncol 12 (2005) 597-608
20. Kang J.C., Wanek L.A., Essner R., Faries M.B., Foshag L.J., and Morton D.L. Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma. J Clin Oncol 23 (2005) 4764-4770
21. Pawlik T.M., Ross M.I., Johnson M.M., Schacherer C.W., McClain D.M., Mansfield P.F., et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 12 (2005) 587-596
22. Thomas J.M. Time to re-evaluate sentinel node biopsy in melanoma post-multicenter selective lymphadenectomy trial. J Clin Oncol 23 (2005) 9443-9444
23. Balch C.M., and Cascinelli N. Sentinel-node biopsy in melanoma. N Engl J Med 355 (2006) 1370-1371
24. Zitelli J.A. Sentinel lymph node evaluations. Adv Dermatol 23 (2007) 47-60
25. Thomas J.M. Prognostic false-positivity of the sentinel node in melanoma. Nat Clin Pract Oncol 5 (2008) 18-23
26. Morton D.L., Cochran A.J., and Thompson J.F. The rationale for sentinel-node biopsy in primary melanoma. Nat Clin Pract Oncol 5 (2008) 510-511
27. Thomas J.M. Concerns relating to the conduct and statistical analysis of the Multicenter Selective Lymphadenectomy Trial (MSLT-1) in patients with melanoma. J Plast Reconstr Aesthet Surg 62 (2009) 442-446
28. Thomas J.M. Sentinel-node biopsy in melanoma. N Engl J Med 356 (2007) 418
29. Fife K., and Thompson J.F. Lymph-node metastases in patients with melanoma: what is the optimum management?. Lancet Oncol 2 (2001) 614-621
30. Sabel M.S., Griffith K.A., Arora A., Shargorodsky J., Blazer III D.G., Rees R., et al. Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy. Surgery 141 (2007) 728-735
31. Bastiaannet E., Beukema J.C., and Hoekstra H.J. Radiation therapy following lymph node dissection in melanoma patients: treatment, outcome and complications. Cancer Treat Rev 31 (2005) 18-26
32. McMasters K.M., Noyes R.D., Reintgen D.S., Goydos J.S., Beitsch P.D., Davidson B.S., et al. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol 86 (2004) 212-223
33. Morton D.L. Sentinel node mapping and an International Sentinel Node Society: current issues and future directions. Ann Surg Oncol 11 3 suppl (2004) 137S-143S
34. Blumenthal R., Banic A., Brand C.U., Ris H.B., and Lardinois D. Morbidity and outcome after sentinel lymph node dissection in patients with early-stage malignant cutaneous melanoma. Swiss Surg 8 (2002) 209-214
35. Kretschmer L., Thoms K.M., Peeters S., Haenssle H., Bertsch H.P., and Emmert S. Postoperative morbidity of lymph node excision for cutaneous melanoma-sentinel lymphonodectomy versus complete regional lymph node dissection. Melanoma Res 18 (2008) 16-21
36. Morton D.L., Cochran A.J., Thompson J.F., Elashoff R., Essner R., Glass E.C., et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 242 (2005) 302-311
37. Rousseau Jr. D.L., Ross M.I., Johnson M.M., Prieto V.G., Lee J.E., Mansfield P.F., et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 10 (2003) 569-574
38. Bleicher R.J., Essner R., Foshag L.J., Wanek L.A., and Morton D.L. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol 21 (2003) 1326-1331
39. Cascinelli N., Belli F., Santinami M., Fait V., Testori A., Ruka W., et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 7 (2000) 469-474
40. Kesmodel S.B., Karakousis G.C., Botbyl J.D., Canter R.J., Lewis R.T., Wahl P.M., et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 12 (2005) 449-458
41. Wright B.E., Scheri R.P., Ye X., Faries M.B., Turner R.R., Essner R., et al. Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg 143 (2008) 892-899
42. Wong S.L., Brady M.S., Busam K.J., and Coit D.G. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol 13 (2006) 302-309
43. Warycha M.A., Zakrzewski J., Ni Q., Shapiro R.L., Berman R.S., Pavlick A.C., et al. Meta-analysis of sentinel lymph node positivity in thin melanoma (
44. Gimotty P.A., Guerry D., Ming M.E., Elenitsas R., Xu X., Czerniecki B., et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol 22 (2004) 3668-3676
45. Sondak V.K., Taylor J.M., Sabel M.S., Wang Y., Lowe L., Grover A.C., et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol 11 (2004) 247-258
46. Thompson J.F., and Shaw H.M. Is sentinel lymph node biopsy appropriate in patients with thin melanomas: too early to tell?. Ann Surg Oncol 13 (2006) 279-281
47. Balch C.M. The role of elective lymph node dissection in melanoma: rationale, results, and controversies. J Clin Oncol 6 (1988) 163-172
48. Carlson G.W., Murray D.R., Hestley A., Staley C.A., Lyles R.H., and Cohen C. Sentinel lymph node mapping for thick (>or=4-mm) melanoma: should we be doing it?. Ann Surg Oncol 10 (2003) 408-415
49. Gershenwald J.E., Mansfield P.F., Lee J.E., and Ross M.I. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol 7 (2000) 160-165
50. Thompson J.F., and Shaw H.M. The prognosis of patients with thick primary melanomas: is regional lymph node status relevant, and does removing positive regional nodes influence outcome?. Ann Surg Oncol 9 (2002) 719-722
51. Caraco C., Celentano E., Lastoria S., Botti G., Ascierto P.A., and Mozzillo N. Sentinel lymph node biopsy does not change melanoma-specific survival among patients with Breslow thickness greater than four millimeters. Ann Surg Oncol 11 (2004) 198S-202S
52. Essner R., Chung M.H., Bleicher R., Hsueh E., Wanek L., and Morton D.L. Prognostic implications of thick (>or=4-mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy. Ann Surg Oncol 9 (2002) 754-761
53. Gutzmer R., Satzger I., Thoms K.M., Völker B., Mitteldorf C., Kapp A., et al. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas. J Dtsch Dermatol Ges 6 (2008) 198-203
54. Balch C.M., Buzaid A.C., Soong S.J., Atkins M.B., Cascinelli N., Coit D.G., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19 (2001) 3635-3648
55. Cascinelli N., Bombardieri E., Bufalino R., Camerini T., Carbone A., Clemente C., et al. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol 24 (2006) 4464-4471
56. Cochran A.J., Wen D.R., Huang R.R., Wang H.J., Elashoff R., and Morton D.L. Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol 17 (2004) 747-755
57. Lee J.H., Essner R., Torisu-Itakura H., Wanek L., Wang H., and Morton D.L. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol 22 (2004) 3677-3684
58. Cadili A., Smylie M., Danyluk J., and Dabbs K. Prediction of nonsentinel lymph node metastasis in malignant melanoma. J Surg Res 154 (2009) 324-329
59. Satzger I., Volker B., Meier A., Kapp A., and Gutzmer R. Criteria in sentinel lymph nodes of melanoma patients that predict involvement of nonsentinel lymph nodes. Ann Surg Oncol 15 (2008) 1723-1732
60. Roka F., Mastan P., Binder M., Okamoto I., Mittlboeck M., Horvat R., et al. Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients. Eur J Surg Oncol 34 (2008) 82-88
61. Govindarajan A., Ghazarian D.M., McCready D.R., and Leong W.L. Histological features of melanoma sentinel lymph node metastases associated with status of the completion lymphadenectomy and rate of subsequent relapse. Ann Surg Oncol 14 (2007) 906-912
62. van Akkooi A.C., de Wilt J.H., Verhoef C., Schmitz P.I., van Geel A.N., Eggermont A.M., et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative?. Ann Oncol 17 (2006) 1578-1585
63. Scheri R.P., Essner R., Turner R.R., Ye X., and Morton D.L. Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. Ann Surg Oncol 14 (2007) 2861-2866
64. Frankel T.L., Griffith K.A., Lowe L., Wong S.L., Bichakjian C.K., Chang A.E., et al. Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma?. Ann Surg Oncol 15 (2008) 2403-2411
65. Gershenwald J.E., Andtbacka R.H., Prieto V.G., Johnson M.M., Diwan A.H., Lee J.E., et al. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol 26 (2008) 4296-4303
66. Wong S.L., Morton D.L., Thompson J.F., Gershenwald J.E., Leong S.P., Reintgen D.S., et al. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol 13 (2006) 809-816
67. Scoggins C.R., Ross M.I., Reintgen D.S., Noyes R.D., Goydos J.S., Beitsch P.D., et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol 24 (2006) 2849-2857
68. Mocellin S., Hoon D.S., Pilati P., Rossi C.R., and Nitti D. Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis of prognosis. J Clin Oncol 25 (2007) 1588-1595
69. Perrott R.E., Glass F., Reintgen D.S., and Fenske N.A. Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in the management of cutaneous malignant melinoma. J Am Acad Dermatol 49 (2003) 567-588